Research programme: aminoglycoside antibacterials - Biolex

Drug Profile

Research programme: aminoglycoside antibacterials - Biolex

Alternative Names: Aminoglycoside (Transport Molecule) research programme - Biolex; Pseudomonal infections therapy research programme - Biolex

Latest Information Update: 16 Apr 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biolex
  • Class Aminoglycosides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 03 Jul 2012 Biolex files for Chapter 7 bankruptcy in the US Bankruptcy Court for the Middle District of North Carolina
  • 06 May 2004 Epicyte Pharmaceutical has been acquired and merged into Biolex
  • 11 Mar 1999 Preclinical development for Cystic fibrosis-associated respiratory tract infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top